SCHEMBL324716

SCHEMBL324716

CCOC(=O)C(C)OS(=O)(=O)C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.38
HSD17B10 Q99714 2/20 0.35
MAPT P10636 2/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 4/20 0.33
KMT2A Q03164 2/20 0.33
IDH1 O75874 1/20 0.32
GRM2 Q14416 1/20 0.32
PIN1 Q13526 1/20 0.32
TSHR P16473 1/20 0.31
ALOX15 P16050 1/20 0.31
ATM Q13315 1/20 0.31
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
CXCR2 P25025 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL701746 1.00 POLB (0.38) POLBHSD17B10MAPTHTTSMN1; SMN2
SCHEMBL324715 1.00 POLB (0.38) POLBHSD17B10MAPTHTTSMN1; SMN2
SCHEMBL7285869 0.84 TSHR (0.36) MAPTSMN1; SMN2ALDH1A1TSHRGAA
SCHEMBL27029062 0.83 ALDH1A1 (0.40) POLBMAPTSMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL8397971 0.82 POLB (0.36) POLBHSD17B10MAPTHTTSMN1; SMN2
SCHEMBL8397975 0.82 POLB (0.36) POLBHSD17B10MAPTHTTSMN1; SMN2
SCHEMBL16584183 0.81 CA14 (0.41) SMN1; SMN2KMT2ACXCR2MEN1
SCHEMBL2797628 0.81 CA14 (0.41) SMN1; SMN2KMT2ACXCR2MEN1
SCHEMBL2598240 0.81 CA14 (0.41) SMN1; SMN2KMT2ACXCR2MEN1
SCHEMBL2326461 0.80 HSD17B10 (0.35) POLBHSD17B10MAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2505085-B2 1996-06-05 JP claimed
EP-0550631-A4 COMPOUNDS HAVING ANTIHYPERTENSIVE AND ANTI-ISCHEMIC PROPERTIES RHONE POULENC RORER INT (US) 1994-08-10 EP claimed
EP-0550631-A1 COMPOUNDS HAVING ANTIHYPERTENSIVE AND ANTI-ISCHEMIC PROPERTIES. RHONE POULENC RORER INT (US) 1993-07-14 EP claimed
WO-1992005177-A1 COMPOUNDS HAVING ANTIHYPERTENSIVE AND ANTI-ISCHEMIC PROPERTIES RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-04-02 WO claimed
EP-3567040-B1 METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES AMGEN INC (US) 2020-09-09 EP disclosed
EP-3567040-A1 METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES Amgen, Inc (US) 2019-11-13 EP disclosed
EP-3013825-B1 METHOD FOR THE PREPARATION OF (1,2,4)-TRIAZOLO(4,3-A)PYRIDINES AMGEN INC (US) 2019-08-07 EP disclosed
US-9351974-B2 Substituted pteridinones for the treatment of cancer OSI Pharmaceuticals, LLC (US) 2016-05-31 US disclosed
US-9351974-B2 Substituted pteridinones for the treatment of cancer OSI Pharmaceuticals, LLC (US) 2016-05-31 US disclosed
US-20140315911-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC 2014-10-23 US disclosed
US-20140315911-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC 2014-10-23 US disclosed
EP-2776444-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC (US) 2014-09-17 EP disclosed
US-6426413-B1 SUCH AS (N-BENZYLOXYCARBONYL-HYDRAZINO)-ACETIC ACID TERT-BUTYL ESTER; FOR PREVENTING AND TREATING INTERLEUKIN-MEDIATED DISEASES, APOPTOSIS, AUTOIMMUNE DISEASES, BONE DISORDERS, PROLIFERATIVE DISORDERS, INFECTIONS, AND DEGENERATIVE DISEASES VERTEX PHARMACEUTICALS INCORPORATED 2002-07-30 US disclosed
US-6395918-B1 Conversion of a hydroxy group in certain alcohols into a fluorosulfonate ester or a trifluoromethylsulfonate ester LOEWENTHAL HANS JACOB EDGAR (IL) 2002-05-28 US disclosed
WO-2001042216-A2 CASPASE INHIBITORS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2001-06-14 WO disclosed
EP-1075463-A1 CONVERSION OF A HYDROXY GROUP IN CERTAIN ALCOHOLS INTO A FLUOROSULFONATE ESTER OR A TRIFLUOROMETHYLSULFONATE ESTER Loewenthal, Hans Jacob Edgar (IL) 2001-02-14 EP disclosed
WO-1999055666-A1 CONVERSION OF A HYDROXY GROUP IN CERTAIN ALCOHOLS INTO A FLUOROSULFONATE ESTER OR A TRIFLUOROMETHYLSULFONATE ESTER LOEWENTHAL HANS JACOB EDGAR (IL) 1999-11-04 WO disclosed
US-5942387-A Combinatorial process for preparing substituted thiophene libraries ELI LILLY AND COMPANY (US) 1999-08-24 US disclosed
EP-0816310-A2 Scavenger assisted combinatorial process for preparing libraries of tertiary amine compounds ELI LILLY AND COMPANY (US) 1998-01-07 EP disclosed
US-5563136-A ADMINISTERING FOR GASTROINTESTINAL OR NERVOUS SYSTEM DISORDERS CONNECTED WITH CHOLECYSTOKININ AND GASTRIN RHONE-POULENC RORER S.A. (FR) 1996-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315911-A1 DIHYDROPTERIDINONES DHPS, DHODH, HYPK POLB 4136/4885HSD17B10 151/4885MAPT 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.